Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Clinical evidence

STRIDE open-label extension

57 evidence topics · 10 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent and serious adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Analysis sets by arm, ITT population
Analysis setOriginal 40 mg QD (N = 82)Original 40 mg BID (N = 83)40 mg QD to 40 mg BID (N = 65)Overall 40 mg BID (N = 148)Overall (N = 165)
ITT population“82”“83”“65”“148”“165”
mITT population“82 (100.0)”“82 (98.8)”“65 (100.0)”“147 (99.3)”“164 (99.4)”
Safety analysis set“82 (100.0)”“82 (98.8)”“65 (100.0)”“147 (99.3)”“164 (99.4)”
PK analysis set“82 (100.0)”“82 (98.8)”“65 (100.0)”“147 (99.3)”“164 (99.4)”
Results
Participant disposition
Disposition by arm, ITT population
DispositionOriginal 40 mg QD (N = 82)Original 40 mg BID (N = 83)40 mg QD to 40 mg BID (N = 65)Overall 40 mg BID (N = 148)Overall (N = 165)
Patients ongoing in study, n (%)“0 (0)”“66 (79.5)”“60 (92.3)”“126 (85.1)”“126 (76.4)”
Patients who switched to 40 mg BID, n (%)“65 (79.3)”“-”“-”“-”“65 (39.4)”
Discontinued: withdrawal by subject“6 (7.3)”“3 (3.6)”“4 (6.2)”“7 (4.7)”“13 (7.9)”
Discontinued: lost to follow-up“3 (3.7)”“6 (7.2)”“1 (1.5)”“7 (4.7)”“10 (6.1)”
Discontinued: inadequate response“6 (7.3)”“1 (1.2)”“0 (0)”“1 (0.7)”“7 (4.2)”
Discontinued: adverse event“1 (1.2)”“4 (4.8)”“0 (0)”“4 (2.7)”“5 (3.0)”
Discontinued: pregnancy“1 (1.2)”“0 (0)”“0 (0)”“0 (0)”“1 (0.6)”
Discontinued: protocol deviation“0 (0)”“1 (1.2)”“0 (0)”“1 (0.7)”“1 (0.6)”
Discontinued: death“0 (0)”“0 (0)”“0 (0)”“0 (0)”“0 (0)”
Baseline characteristics
Demographic and baseline characteristics by original dose assignment, ITT population
CharacteristicOriginal 40 mg QD (N = 82)Original 40 mg BID (N = 83)Overall (N = 165)
Age (y), mean (SD)“47.5 (12.7)”“50.8 (12.1)”“49.2 (12.4)”
Male, n (%)“56 (68.3)”“61 (73.5)”“117 (70.9)”
Female, n (%)“26 (31.7)”“22 (26.5)”“48 (29.1)”
Race: Asian, n (%)“7 (8.5)”“4 (4.8)”“11 (6.7)”
Race: Black or African American, n (%)“5 (6.1)”“1 (1.2)”“6 (3.6)”
Race: Native Hawaiian or Other Pacific Islander, n (%)“1 (1.2)”“2 (2.4)”“3 (1.8)”
Race: White, n (%)“63 (76.8)”“70 (84.3)”“133 (80.6)”
Race: Other, n (%)“6 (7.3)”“5 (6.0)”“11 (6.7)”
Ethnicity: Hispanic or Latino, n (%)“26 (31.7)”“25 (30.1)”“51 (30.9)”
Weight (kg), mean (SD)“98.1 (28.5)”“94.0 (23.2)”“96.0 (26.0)”
BMI (kg/m2), mean (SD)“33.1 (8.8)”“31.7 (7.4)”“32.4 (8.1)”
Duration of psoriasis (y), mean (SD)“17.2 (10.9)”“22.3 (14.3)”“19.8 (13.0)”
Prior treatment with biologics, n (%)“37 (45.1)”“42 (50.6)”“79 (47.9)”
Prior treatment with JAKi, n (%)“1 (1.2)”“3 (3.6)”“4 (2.4)”
PASI, mean (SD)“10.2 (7.2)”“6.8 (7.0)”“8.5 (7.2)”
sPGA score 0, n (%)“1 (1.2)”“5 (6.0)”“6 (3.6)”
sPGA score 1, n (%)“10 (12.2)”“26 (31.3)”“36 (21.8)”
sPGA score 2, n (%)“19 (23.2)”“19 (22.9)”“38 (23.0)”
sPGA score 3, n (%)“39 (47.6)”“23 (27.7)”“62 (37.6)”
sPGA score 4, n (%)“12 (14.6)”“7 (8.4)”“19 (11.5)”
BSA involvement (%), mean (SD)“12.9 (13.4)”“8.7 (11.1)”“10.8 (12.5)”
DLQI, mean (SD)“5.8 (5.8)”“4.5 (4.8)”“5.2 (5.3)”
Average pruritus NRS score, mean (SD)“4.6 (3.0)”“4.0 (3.1)”“4.3 (3.1)”
Efficacy results
Week 28 and week 52 skin responses by original and overall 40 mg twice-daily groups, mITT population, mNRI
EndpointWeek 28, original 40 mg QD (N = 80)Week 52, original 40 mg BID (N = 80)Week 52, overall 40 mg BID (N = 144)
PASI-75, n (%)“54 (67.5)”“62 (77.5)”“112 (77.8)”
PASI-75, 95% CI“56.1, 77.6”“66.8, 86.1”“70.1, 84.3”
PASI-90, n (%)“36 (45.0)”“49 (61.3)”“90 (62.5)”
PASI-90, 95% CI“33.8, 56.5”“49.7, 71.9”“54.1, 70.4”
PASI-100, n (%)“15 (18.8)”“31 (38.8)”“47 (32.6)”
PASI-100, 95% CI“10.9, 29.0”“28.1, 50.3”“25.1, 40.9”
sPGA-0/1, n (%)“41 (51.3)”“49 (61.3)”“86 (59.7)”
sPGA-0/1, 95% CI“39.8, 62.6”“49.7, 71.9”“51.2, 67.8”
sPGA-0, n (%)“15 (18.8)”“31 (38.8)”“47 (32.6)”
sPGA-0, 95% CI“10.9, 29.0”“28.1, 50.3”“25.1, 40.9”
Improvement in PASI response category from STRIDE week 12 to extension week 52, 40 mg twice daily, mITT population
Responder status at week 12 of STRIDENImprovement to PASI-75, n (%)Improvement to PASI-90, n (%)Improvement to PASI-100, n (%)Any improvement, n (%)
Below PASI-75“38”“7 (18.4)”“8 (21.1)”“12 (31.6)”“27 (71.1)”
PASI-75 and below PASI-90“24”“----”“4 (16.7)”“10 (41.7)”“14 (58.3)”
PASI-90 and below PASI-100“11”“----”“----”“4 (36.4)”“4 (36.4)”
Total“73”“----”“----”“----”“45 (61.6)”
Health-related quality of life and patient-reported outcomes
Week 28 and week 52 patient-reported outcomes by original and overall 40 mg twice-daily groups, mITT population, mNRI
EndpointWeek 28, original 40 mg QD (N = 80)Week 52, original 40 mg BID (N = 80)Week 52, overall 40 mg BID (N = 144)
DLQI 0/1, n (%)“41 (51.3)”“49 (61.3)”“87 (60.4)”
DLQI 0/1, 95% CI“39.8, 62.6”“49.7, 71.9”“51.9, 68.5”
DLQI 4-point decrease, n (%)“49 (61.3)”“55 (68.8)”“103 (71.5)”
DLQI 4-point decrease, 95% CI“49.7, 71.9”“57.4, 78.7”“63.4, 78.7”
Average pruritus NRS score below 4, n (%)“54 (67.5)”“65 (81.3)”“115 (79.9)”
Average pruritus NRS score below 4, 95% CI“56.1, 77.6”“71.0, 89.1”“72.4, 86.1”
Worst pruritus NRS score below 4, n (%)“51 (63.8)”“63 (78.8)”“112 (77.8)”
Worst pruritus NRS score below 4, 95% CI“52.2, 74.2”“68.2, 87.1”“70.1, 84.3”
Improvement in worst pruritus NRS score of at least 4, post-hoc, n (%)“44 (55.0)”“47 (58.8)”“89 (61.8)”
Improvement in worst pruritus NRS score of at least 4, post-hoc, 95% CI“43.5, 66.2”“47.2, 69.6”“53.3, 69.8”
Safety results
Adverse events with exposure-adjusted incidence rates through week 52, safety analysis population
Event, n (%) [EAIR]Original 40 mg QD (N = 82)Overall 40 mg BID (N = 147)Overall (N = 164)
Patients with at least 1 TEAE“50 (61.0) [122.76]”“73 (49.7) [102.33]”“108 (65.9) [108.18]”
Patients with TEAE leading to study drug discontinuation“1 (1.2) [1.55]”“5 (3.4) [4.19]”“6 (3.7) [3.26]”
Patients with TEAE grade 3 or higher“3 (3.7) [4.66]”“6 (4.1) [5.12]”“8 (4.9) [4.42]”
Upper respiratory tract infection“3 (3.7) [4.71]”“13 (8.8) [11.66]”“16 (9.8) [9.20]”
Nasopharyngitis“10 (12.2) [16.88]”“6 (4.1) [5.15]”“14 (8.5) [8.09]”
COVID-19“3 (3.7) [4.74]”“8 (5.4) [6.88]”“11 (6.7) [6.17]”
Headache“5 (6.1) [8.28]”“5 (3.4) [4.28]”“10 (6.1) [5.71]”
Patients with at least 1 treatment-emergent SAE“2 (2.4) [3.10]”“4 (2.7) [3.39]”“6 (3.7) [3.29]”
Patients with SAEs related to study drug“2 (2.4) [3.10]”“2 (1.4) [1.67]”“4 (2.4) [2.17]”
Patients with TEAE leading to death“0 (0) [-]”“0 (0) [-]”“0 (0) [-]”
Study limitations
Summary
  • The authors state that this was an open-label study with limited sample size and no placebo or active comparator.
  • No formal power calculation was performed; the sample consisted of STRIDE completers who qualified and chose to enroll. The extension was not initiated in the Czech Republic, which made 25 STRIDE completers ineligible, and the study was conducted at North American sites only.
  • Dose assignment followed the STRIDE arm for participants from the 10 mg QD and 20 mg QD arms (40 mg QD) and the 20 mg BID and 40 mg BID arms (40 mg BID); participants from the placebo and 40 mg QD arms were allocated to either dose. The ClinicalTrials.gov record lists the allocation as randomized.
  • A protocol amendment on 2 January 2024 moved all participants to 40 mg BID between weeks 40 and 64, so the overall 40 mg BID group (N = 148, intent-to-treat) includes 65 participants who switched from 40 mg QD.
  • Efficacy baseline was STRIDE Day 1, and participants entered the extension with a mean PASI of 8.5. Responder analyses used modified nonresponder imputation, carrying the last observation forward for discontinuations other than for AEs or inadequate response.
  • Week 52 PASI 100 with 40 mg BID is 39% in the article text, 31 of 80 (38.8%) in the original 40 mg BID group, and 47 of 144 (32.6%) in the overall 40 mg BID group. Itch control in the original 40 mg BID group is reported as “NRS≤4, 81.3%” in a press release and as average pruritus NRS below 4 in 65 participants (81.3%) in the article table.
  • Data cutoffs differ: the supplement includes data from 18 November 2024, and a congress poster by Blauvelt et al. displays safety data from the 06 SEP 2024 data cut. The treat-to-target analyses and the analysis of an improvement of at least 4 points in worst pruritus NRS are post hoc.
  • The study is ongoing; 126 participants (76.4%) were continuing treatment at the 52-week data cut-off, and study completion is estimated for 2027-12-31.